Skip to main content

Table 1 General characteristics of studies. Values are numbers (percentages) unless stated otherwise

From: Luteal phase support for in vitro fertilization/intracytoplasmic sperm injection fresh cycles: a systematic review and network meta-analysis

Characteristics Live birth (n = 25) Ongoing pregnancy (n = 43)
Study characteristics
 Median (range) study sample size 355 (38–1983) 237 (38–1983)
Continent
 North America 5 (20) 9 (21)
 Europe 9 (36) 17 (40)
 Asia 7 (28) 11 (26)
 World wide 2 (8) 2 (5)
 Other 2 (8) 4 (9)
Type of interventions/controls
 Placebo/no LPS treatment 2 (8) 6 (14)
 HCG 2 (8) 5 (12)
 Progesterone 24 (96) 39 (91)
 Combineda 6 (24) 11 (26)
Patient characteristics
 Median (range) age (years); No in group 32.4 (28.4–35.5); n = 24 32.1 (28.4–35.4); n = 40
Ovarian stimulation
 Long GnRH agonist protocol 14 (56) 24 (56)
 GnRH antagonist protocol 1 (4) 5 (12)
 Other protocol 4 (16) 6 (14)
 Combined 6 (24) 8 (19)
Fertilization
 IVF 13 (52) 23 (53)
 ICSI 2 (8) 7 (16)
 IVF/ICSI 10 (40) 13 (30)
Timing LPS after oocyte retrieval
 Within 48 h 18 (72) 31 (72)
 48–96 h 4 (16) 12 (28)
 Not stated 5 (20) 5 (12)
  1. a Combined progesterone with HCG, oestrogen or GnRH agonists. Abbreviations LPS luteal phase support, HCG human chorionic gonadotrophin, GnRH gonadotropin releasing hormone, IVF in vitro fertilization, ICSI intracytoplasmic sperm injection